Writing the Integrated Benefit-Risk Evaluation Section in a PBRER

Introduction

The Integrated Benefit-Risk Evaluation is the scientific conclusion of the Periodic Benefit-Risk Evaluation Report (PBRER). Every preceding section contributes evidence that is ultimately synthesised here into an overall assessment of whether the benefits of the medicinal product continue to outweigh its risks for the authorised indications and approved conditions of use.

Unlike earlier sections that describe or evaluate individual aspects of the safety profile, this section integrates evidence relating to efficacy or effectiveness, important identified risks, important potential risks, missing information, patient exposure, risk minimisation measures and newly emerging safety information.

The purpose is not merely to state that the benefit-risk balance remains positive. Rather, the reviewer should explain why that conclusion is scientifically justified using the cumulative evidence available at the Data Lock Point.

This section therefore represents the highest level of aggregate medical assessment within the PBRER.

Regulatory Basis

The requirement to provide an integrated benefit-risk evaluation is established in ICH E2C(R2) and reflected in EU Good Pharmacovigilance Practices (GVP) Module VII.

The evaluation should consider the cumulative body of evidence available at the Data Lock Point and determine whether the medicinal product's overall benefit-risk profile has changed during the reporting interval.

Where appropriate, the discussion should also explain whether new information supports changes to product information, additional pharmacovigilance activities or further risk minimisation measures.

The integrated evaluation should therefore represent the logical conclusion arising from all previous sections of the report.

Purpose of the Integrated Benefit-Risk Evaluation

The purpose of this section is not to repeat the discussions already presented elsewhere within the PBRER.

Instead, it should answer a single scientific question:

Considering all available evidence, has the overall benefit-risk balance of the medicinal product changed during the reporting interval?

The reviewer should integrate information relating to benefits, risks and remaining uncertainties into one balanced scientific conclusion.

Importantly, this evaluation concerns the medicinal product as a whole rather than isolated safety issues.

Consequently, individual risks should not be considered independently of therapeutic benefits, clinical context, patient populations or available treatment alternatives.

Relationship to Earlier Sections

The Integrated Benefit-Risk Evaluation depends upon the scientific assessments presented throughout the PBRER.

These include:

• Reference Safety Information;
• estimated patient exposure;
• summary tabulations;
• signal evaluations;
• evaluation of important identified risks;
• evaluation of important potential risks;
• missing information;
• clinical trial findings;
• PASS;
• scientific literature;
• regulatory actions.

Earlier sections establish the evidence.

The Integrated Benefit-Risk Evaluation explains what that evidence collectively means for continued clinical use of the medicinal product.

Writing Tip

Earlier sections answer individual scientific questions.

The Integrated Benefit-Risk Evaluation answers the overall regulatory question.

Principles of Integrated Benefit-Risk Evaluation

The Integrated Benefit-Risk Evaluation should not be viewed as a summary of earlier sections. Instead, it is a higher-level scientific assessment that synthesises all relevant evidence into a coherent conclusion regarding the medicinal product's overall benefit-risk balance.

The reviewer should therefore avoid discussing benefits and risks independently. Rather, each should be interpreted in the context of the other.

The central question is not whether important risks exist. All medicines have risks.

Instead, the question is whether the recognised benefits continue to outweigh the recognised and potential risks for the authorised indications and approved conditions of use.

Accordingly, the evaluation should remain focused on the overall clinical use of the medicinal product rather than isolated safety observations.

Integrating Benefit and Risk Evidence

Scientific integration requires consideration of both positive and negative evidence.

Benefits should be evaluated together with:

• important identified risks;

• important potential risks;

• remaining areas of missing information;

• effectiveness of risk minimisation measures;

• changes in clinical practice;

• availability of therapeutic alternatives;

• patient populations receiving treatment.

No single component should dominate the evaluation in isolation.

For example, identification of a new important identified risk does not automatically indicate that the benefit-risk balance has become unfavourable.

Similarly, demonstration of important therapeutic benefit does not diminish the need to evaluate serious safety concerns objectively.

The integrated assessment should explain how all available evidence contributes to the overall conclusion.

Determining Whether the Benefit-Risk Balance Has Changed

One of the most important responsibilities of the aggregate physician is determining whether cumulative evidence has materially altered the previous benefit-risk assessment.

Questions that should be considered include:

• Have new important identified risks emerged?

• Have recognised risks become more frequent or more severe?

• Have important uncertainties been resolved?

• Have new evidence or studies strengthened confidence in the benefits?

• Have new patient populations altered interpretation of the benefit-risk balance?

• Have additional risk minimisation measures improved safe use?

• Have changes to product information adequately addressed newly recognised risks?

The objective is to evaluate change over time rather than simply restate the current safety profile.

Weighing Benefits Against Risks

Integrated evaluation requires consideration of the clinical importance of both benefits and risks.

Factors influencing benefit include:

• magnitude of therapeutic effect;

• durability of benefit;

• quality of evidence supporting effectiveness;

• unmet medical need;

• availability of alternative therapies;

• impact upon clinically meaningful outcomes.

Factors influencing risk include:

• seriousness of adverse reactions;

• reversibility;

• preventability;

• frequency;

• affected patient populations;

• effectiveness of existing risk minimisation measures.

The evaluation should explain how these considerations collectively influence the overall benefit-risk profile without implying that a formal numerical weighting process has been applied.

Considering the Clinical Context

Benefit-risk evaluation cannot be performed independently of the clinical setting in which the medicinal product is used.

The same safety concern may have different implications depending upon:

• disease severity;

• prognosis without treatment;

• availability of alternative therapies;

• duration of treatment;

• patient preferences where relevant;

• authorised indications;

• vulnerable populations.

For example, acceptance of serious toxicity may differ substantially between life-threatening malignancies and self-limiting conditions.

Accordingly, benefit-risk conclusions should always be interpreted within the authorised therapeutic context.

Integrating Remaining Uncertainty

Uncertainty is an inherent component of every benefit-risk evaluation.

Examples include:

• important potential risks;

• areas of missing information;

• limited long-term exposure;

• rare adverse reactions;

• use in underrepresented populations;

• ongoing PASS;

• evolving real-world evidence.

The objective is not to eliminate uncertainty but to determine whether the remaining uncertainty materially alters the overall benefit-risk balance.

Where important uncertainty remains, this should be described transparently together with any planned pharmacovigilance activities intended to reduce that uncertainty.

Medical Review Consideration

Integrated benefit-risk evaluation is not a process of counting benefits and risks. It is a process of determining whether the cumulative scientific evidence continues to support the medicinal product's use under the authorised conditions, while recognising both established knowledge and remaining uncertainty.

Common Benefit-Risk Evaluation Scenarios

The integrated benefit-risk balance rarely changes because of a single observation. More commonly, it evolves gradually as cumulative evidence improves understanding of both the benefits and risks of the medicinal product.

The following scenarios illustrate common situations encountered during preparation of a PBRER. They are intended to demonstrate the principles of scientific reasoning rather than prescribe a single regulatory outcome.

Scenario 1 – New Important Identified Risk but Unchanged Benefit-Risk Balance

Identification of a new important identified risk does not automatically result in an unfavourable benefit-risk balance.

The reviewer should consider:

• the seriousness of the risk;
• its frequency;
• whether the risk is predictable;
• whether it can be prevented or monitored;
• whether effective treatment exists;
• the magnitude of therapeutic benefit;
• the clinical need for the medicinal product.

For example, recognition of a rare but monitorable adverse reaction may justify updates to product information without materially altering the overall benefit-risk balance.

The evaluation should explain why the benefits continue to outweigh the newly recognised risk.

Scenario 2 – Improved Characterisation of an Existing Risk

Many reporting intervals do not identify new risks but improve understanding of existing ones.

Examples include:

• identification of high-risk patient groups;
• clarification of time to onset;
• improved understanding of dose dependency;
• identification of early warning signs;
• improved management strategies.

In these situations, the overall benefit-risk balance frequently remains unchanged despite important advances in scientific knowledge.

The discussion should emphasise that refinement of risk characterisation represents scientific progress rather than deterioration of the safety profile.

Scenario 3 – Benefit-Risk Changes Only in a Particular Population

The overall benefit-risk balance may remain favourable while becoming less favourable in specific patient populations.

Examples include:

• patients with severe renal impairment;

• patients with hepatic impairment;

• paediatric patients;

• elderly patients;

• pregnant women;

• patients with important comorbidities.

Rather than presenting a single universal conclusion, the evaluation should explain how the benefit-risk profile differs across authorised patient populations.

Where these differences justify revised contraindications, warnings or monitoring recommendations, this should be discussed explicitly.

Scenario 4 – Improved Risk Minimisation Restores Benefit-Risk Balance

Additional risk minimisation measures may substantially reduce the clinical impact of recognised risks.

Examples include:

• laboratory monitoring;

• pregnancy prevention programmes;

• educational materials;

• revised dosing recommendations;

• contraindications;

• strengthened warnings;

• healthcare professional training.

Where effective risk minimisation reduces preventable harm, the integrated evaluation should explain how these measures influence the overall benefit-risk assessment.

The conclusion should reflect the medicinal product as authorised and used in clinical practice, including applicable risk minimisation measures.

Scenario 5 – New Therapeutic Alternatives

Benefit-risk evaluation should always be interpreted within the contemporary therapeutic landscape.

Availability of new treatment options may influence the clinical importance of both benefits and risks even when the medicinal product itself has not changed.

For example, a medicine associated with significant toxicity may retain a favourable benefit-risk balance where no effective alternatives exist but become less favourable after introduction of safer therapies with comparable effectiveness.

The evaluation should therefore consider current standards of care where they materially influence interpretation of the authorised indications.

Scenario 6 – Conflicting Benefit and Risk Evidence

Occasionally, new evidence strengthens understanding of both benefits and risks simultaneously.

Examples include:

• improved long-term effectiveness together with recognition of delayed toxicity;

• identification of a new therapeutic indication accompanied by important new adverse reactions;

• increased effectiveness in selected patient populations together with increased toxicity in others.

Rather than considering these findings independently, the reviewer should explain how they interact to influence the overall benefit-risk balance.

The integrated evaluation should demonstrate balanced scientific reasoning rather than separate descriptions of benefits and risks.

Scenario 7 – Benefit-Risk Balance Remains Unchanged Despite New Information

One of the most common conclusions reached within a PBRER is that new information has become available without materially changing the overall benefit-risk balance.

Examples include:

• additional case reports consistent with the recognised safety profile;

• confirmatory epidemiological studies;

• expected findings from ongoing pharmacovigilance activities;

• refinement of recognised risks without altering their clinical significance;

• additional exposure confirming previous conclusions.

Where this occurs, authors should explain why the cumulative evidence confirms the previous assessment rather than simply stating that the benefit-risk balance remains favourable.

Scientific justification is considerably more valuable than repetition of the conclusion.

Scenario 8 – Benefit-Risk Balance Changes

Occasionally, cumulative evidence indicates that the overall benefit-risk profile has changed.

Examples may include:

• identification of a serious previously unrecognised adverse reaction that cannot be adequately minimised;

• evidence demonstrating reduced clinical effectiveness in authorised use;

• important new information affecting the principal therapeutic benefit;

• emergence of substantial evidence altering the overall balance between benefits and risks.

Where this occurs, the discussion should explain:

• which evidence changed the previous understanding;

• why previous conclusions are no longer appropriate;

• the impact on authorised use;

• changes to product information;

• additional pharmacovigilance activities;

• implementation of further risk minimisation measures.

The reasoning supporting such conclusions should be particularly clear because these evaluations frequently have significant regulatory consequences.

Medical Review Consideration

The central question is not whether new information has emerged.

The central question is whether the cumulative evidence has changed the scientific understanding of the medicinal product sufficiently to alter the overall balance between its benefits and risks under the authorised conditions of use.

Reaching and Defending the Overall Benefit-Risk Conclusion

The Integrated Benefit-Risk Evaluation should culminate in a clear scientific conclusion supported by the evidence presented throughout the PBRER.

The conclusion should never appear abrupt or unsupported. Instead, it should represent the logical outcome of the cumulative assessments presented in earlier sections.

Readers should be able to follow the progression from individual observations, through signal evaluation and risk characterisation, to the overall benefit-risk conclusion without encountering new evidence or unexpected reasoning.

The Conclusion Should Be Evidence-Based

The overall conclusion should reflect the cumulative evidence available at the Data Lock Point.

It should not be based upon:

• organisational preference;

• historical conclusions;

• commercial considerations;

• expectations regarding regulatory outcome;

• assumptions unsupported by evidence.

Instead, the discussion should explain why the available evidence supports the stated conclusion.

Where important uncertainty remains, the conclusion should acknowledge that uncertainty explicitly rather than implying a level of confidence unsupported by the available data.

Avoid Introducing New Evidence

The Integrated Benefit-Risk Evaluation should synthesise information already presented elsewhere within the PBRER.

Accordingly, this section should generally avoid introducing:

• new case reports;

• previously undiscussed studies;

• additional literature reviews;

• new statistical analyses;

• new signal evaluations;

• new regulatory actions.

If important evidence has not been discussed earlier, the appropriate solution is usually to revise the relevant preceding section rather than introduce it for the first time within the final integrated assessment.

This approach improves internal consistency and allows reviewers to understand how the evidence contributed to the overall conclusion.

Explain Why the Conclusion Has—or Has Not—Changed

One of the most valuable parts of the Integrated Benefit-Risk Evaluation is explaining whether the current conclusion differs from that of the previous PBRER.

Where the conclusion remains unchanged, authors should explain why.

Examples include:

• cumulative evidence confirms previous conclusions;

• new information remains consistent with the recognised safety profile;

• additional exposure has not identified clinically meaningful changes;

• important uncertainties remain unchanged;

• existing risk minimisation measures continue to be appropriate.

Conversely, where the benefit-risk balance has changed, the evaluation should identify the evidence responsible for that change and explain its scientific significance.

The emphasis should remain on explaining the evolution of knowledge rather than simply reporting the final conclusion.

Consistency with Regulatory Actions

The Integrated Benefit-Risk Evaluation should remain consistent with regulatory actions described elsewhere in the PBRER.

For example:

• updates to the Company Core Safety Information (CCSI);

• revisions to the Reference Safety Information (RSI);

• changes to product information;

• implementation of additional risk minimisation measures;

• initiation of additional pharmacovigilance activities;

• requests for further studies.

These actions should arise naturally from the scientific evaluation.

Conversely, significant regulatory actions without corresponding discussion within the integrated evaluation may create uncertainty regarding the rationale for those actions.

Writing Balanced Conclusions

Benefit-risk conclusions should remain balanced and proportionate.

Avoid overly definitive statements where important uncertainty persists.

Similarly, avoid unnecessarily cautious wording where the available evidence clearly supports the conclusion.

The language should accurately reflect the strength, consistency and limitations of the available evidence.

Appropriate conclusions often acknowledge both what is known and what remains uncertain.

Maintaining Internal Consistency

Before finalising the PBRER, authors should review the report as an integrated scientific document.

The following questions should be considered:

• Does the Integrated Benefit-Risk Evaluation accurately reflect the conclusions of the signal evaluations?

• Are changes described within the Evaluation of Risks section reflected appropriately?

• Is the discussion consistent with changes to the Reference Safety Information?

• Are exposure estimates appropriately considered?

• Are conclusions regarding remaining uncertainty consistent throughout the report?

• Do proposed pharmacovigilance activities align with the identified uncertainties?

Internal consistency is one of the strongest indicators of a well-prepared aggregate report.

Writing Tip

The final conclusion should never surprise the reader.

After reading the preceding sections, an experienced reviewer should recognise that the integrated benefit-risk conclusion is the logical scientific consequence of the cumulative evidence presented throughout the PBRER.

Common Mistakes

The Integrated Benefit-Risk Evaluation is often the most scrutinised section of the PBRER because it represents the Marketing Authorisation Holder's overall scientific conclusion. Deficiencies usually arise not because the conclusion is incorrect, but because the reasoning supporting that conclusion is incomplete, inconsistent or insufficiently transparent.

The following deficiencies are encountered frequently during internal peer review, regulatory assessment and pharmacovigilance inspections.

Scientific Mistakes

The most common scientific mistake is treating benefit-risk evaluation as a summary rather than an integration of evidence.

Examples include:

• simply repeating the conclusions from earlier sections without integrating them;

• discussing benefits and risks independently without explaining their interaction;

• giving disproportionate weight to one new safety finding while ignoring the totality of evidence;

• failing to consider remaining uncertainties;

• failing to consider changes in clinical practice or therapeutic alternatives;

• confusing absence of new safety concerns with evidence that benefit-risk has improved;

• concluding that benefit-risk has changed without explaining the scientific basis.

The integrated evaluation should demonstrate scientific reasoning rather than scientific repetition.

Writing Mistakes

Common writing deficiencies include:

• introducing new evidence for the first time within the integrated evaluation;

• presenting unsupported conclusions;

• using vague statements such as "the benefit-risk balance remains favourable" without explaining why;

• failing to distinguish observations from interpretation;

• excessive repetition of previous sections;

• inconsistent terminology across the report;

• conclusions that do not logically follow from the preceding evidence.

Every paragraph should contribute directly to answering the central scientific question:

Has the cumulative evidence altered the overall benefit-risk balance?

Governance Mistakes

Benefit-risk conclusions should remain consistent with the remainder of the pharmacovigilance system.

Common governance deficiencies include:

• inconsistency with the Risk Management Plan (RMP);

• inconsistency with the Company Core Safety Information (CCSI);

• inconsistency with the Reference Safety Information (RSI);

• failure to reflect completed signal evaluations;

• failure to incorporate relevant partner safety information available before the Data Lock Point;

• inconsistency between proposed pharmacovigilance activities and identified uncertainties;

• inadequate documentation supporting important scientific decisions.

Consistency across aggregate reports, product information and pharmacovigilance governance documents strengthens regulatory confidence.

Inspection and Regulatory Assessment Considerations

During regulatory assessment, reviewers focus not only on the final benefit-risk conclusion but also on the scientific reasoning supporting that conclusion.

Typical assessment questions include:

• Does the conclusion reflect the cumulative evidence presented throughout the PBRER?

• Have important benefits and important risks both been considered?

• Have contradictory findings been discussed appropriately?

• Are important uncertainties acknowledged?

• Is the conclusion proportionate to the strength of the available evidence?

• Are proposed regulatory actions scientifically justified?

• Is the discussion internally consistent with earlier sections of the report?

During pharmacovigilance inspections, inspectors may additionally evaluate:

• governance of aggregate medical review;

• multidisciplinary review and approval processes;

• traceability between signal evaluation, risk evaluation and benefit-risk conclusions;

• documentation supporting important scientific judgements;

• implementation of regulatory commitments arising from previous PBRERs;

• consistency between the PBRER, Risk Management Plan, Company Core Safety Information and product information.

Inspectors frequently examine successive PBRERs to determine whether the organisation's scientific reasoning has evolved appropriately as new evidence accumulated.

Inspection Insight

Inspectors are rarely looking for a particular benefit-risk conclusion. They are evaluating whether the organisation can demonstrate a consistent, evidence-based and reproducible process for reaching that conclusion.

Key Takeaways

The Integrated Benefit-Risk Evaluation represents the highest level of scientific assessment within the PBRER.

Its purpose is not to repeat earlier discussions but to integrate all relevant evidence relating to benefits, risks and remaining uncertainties into a coherent evaluation of the medicinal product's overall benefit-risk balance.

High-quality evaluations explain how scientific understanding has evolved, distinguish clearly between observations, interpretation and regulatory consequences, acknowledge uncertainty where appropriate and ensure that the final conclusion follows logically from the cumulative evidence presented throughout the report.

Ultimately, the strength of the evaluation lies not in stating that the benefit-risk balance is favourable or unfavourable, but in demonstrating transparently why that conclusion is scientifically justified.

How a Senior Aggregate Physician Thinks

Experienced aggregate physicians rarely ask:

"Is the benefit-risk balance still favourable?"

Instead, they ask:

"If I were a regulator reviewing this product for the first time, would the cumulative evidence presented in this report naturally lead me to the same conclusion?"

They do not view benefit-risk evaluation as the final section of a report. They view it as the culmination of an evidence chain extending from individual case reports through signal evaluation, risk characterisation and scientific integration.

They recognise that benefit-risk assessment is dynamic. New evidence may strengthen confidence, reduce uncertainty, redefine recognised risks or refine clinical use without necessarily changing the overall regulatory conclusion.

Their objective is therefore not merely to reach a conclusion but to ensure that every conclusion is scientifically transparent, reproducible and proportionate to the available evidence.

Continue Reading

• [[benefit-risk-evaluation-in-pharmacovigilance]]
• [[writing-the-overall-conclusion-section-in-a-pbrer]]
• [[writing-the-evaluation-of-risks-and-new-information-section-in-a-pbrer]]
• [[writing-the-signal-evaluation-section-in-a-pbrer]]
• [[risk-management-plans]]
• [[reference-safety-information-in-pharmacovigilance]]
• [[scientific-writing-in-pharmacovigilance]]

References

Primary Regulatory References

1. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report.

2. European Medicines Agency. Good Pharmacovigilance Practices (GVP) Module VII – Periodic Safety Update Report.

3. Commission Implementing Regulation (EU) No 520/2012.

4. Directive 2001/83/EC.

5. Regulation (EC) No 726/2004.

Supporting Regulatory Guidance

1. EMA Questions & Answers on PSURs.

2. EMA Procedural Guidance for PSUSA.

3. EMA guidance on post-authorisation benefit-risk evaluation and product information.

Scientific References

1. CIOMS Working Group reports on benefit-risk assessment.

2. CIOMS VIII: Practical Aspects of Signal Detection in Pharmacovigilance.

3. ENCePP Guide on Methodological Standards in Pharmacoepidemiology.

4. ISPE Good Pharmacoepidemiology Practices.

5. Selected peer-reviewed publications on benefit-risk assessment, causal inference and regulatory decision-making.